Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

@article{Cannon2010ComparisonOT,
  title={Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.},
  author={Christopher Paul Cannon and Robert A. Harrington and Stefan N James and Diego Ardissino and Richard C. Becker and H{\aa}kan U. Emanuelsson and Steen Elkj{\ae}r Husted and Hugo S Katus and M{\'a}ty{\'a}s Keltai and Nardev S. Khurmi and Frederic Kontny and Basil S. Lewis and Philippe Gabriel Steg and Robert F. Storey and Daniel Wojdyla and Lars Wallentin},
  journal={Lancet},
  year={2010},
  volume={375 9711},
  pages={283-93}
}
BACKGROUND Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of administration in patients with acute coronary syndromes. We compared ticagrelor, a more potent reversible P2Y12 inhibitor with clopidogrel in such patients. METHODS At randomisation, an invasive strategy was planned for 13 408 (72.0%) of 18 624 patients hospitalised for acute coronary syndromes (with or without ST elevation). In a double-blind… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 214 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Ticagrelor : the fi rst reversibly binding oral P 2 Y receptor antagonist

  • JJ VanGiezen, L Nilsson, P Berntsson
  • Cardiovasc Ther
  • 2009

Similar Papers

Loading similar papers…